We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Instrument Measures Genetic Variations of HIV

By HospiMedica staff writers
Posted on 22 May 2007
A new diagnostic instrument detects and measures human immunodeficiency virus (HIV)-1 and all known genetic variations of the virus.

The m2000 instrument and HIV-1 test represents substantial improvement over existing methods. More...
The assay is designed to detect and precisely measure levels of the HIV circulating in a patient's blood (viral load), including the three major groups of HIV-1 as well as non-B subtypes.

The Real-Time HIV-1 test was developed for use on the Abbott Laboratories' (Abbott Park, IL, USA) m2000 system, an automated instrument for DNA and RNA testing in molecular laboratories. The m2000 system is based on real-time polymerase chain reaction (PCR) technology and is designed to efficiently detect and measure viruses and bacteria in patient samples in less than five hours, compared to other testing methods that may take up to two days.

Abbott has received U.S. Food and Drug Administration (FDA) approval to market the Abbott Real-Time HIV-1 viral load test for use on the company's m2000 automated instrument system.

HIV-1 can be divided into groups M (major), O (outlier), and N (new). The vast majority of isolates cluster in the M group. Distinct lineages within group M have also been identified, and these lineages are called strains or subtypes. They include subtype designations A through G. While HIV-1 subtype B continues to be the most common strain found in the United States, studies suggest that an increasing number of newly diagnosed patients are infected with non-B subtype viruses and various circulating recombinants as a result of the influx of immigrants from countries where variant strains of HIV are more common.

The Abbott Real-Time HIV-1 assay is a sensitive viral load test, with a broad dynamic range, capable of quantitating HIV-1 in plasma down to as few as 40 RNA molecules per ml and up to as many as 10 million molecules per ml. The assay is intended for use in conjunction with clinical presentation and other laboratory markers as an indicator of disease prognosis and for use as an aid in assessing viral response to antiretroviral treatment as measured by changes in plasma HIV-1 RNA levels.

Additional products in development for the Abbott m2000 system include assays for hepatitis C virus (HCV), hepatitis B virus (HBV), HCV genotyping, chlamydia, and gonorrhea. Abbott markets the m2000 system and a menu of tests throughout the world as part of a strategic alliance with Celera (Rockville, MD, USA).


Related Links:
Abbott

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Hypodermic Syringe
SurTract™ Safety Syringe
Tourniquet System
heidi– mein Tourniquet
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: New findings show that chemotherapy plus immunotherapy before surgery produced greater tumor destruction than immunotherapy alone in head and neck cancer patients (Image Credit: Adobe Stock)

Combination Therapy Before Surgery Drives Stronger Tumor Reduction in Head and Neck Cancer

Patients with head and neck cancer who are scheduled for surgery often face a waiting period with limited treatment, creating an opportunity to reduce viable tumor burden before the operation.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.